HSG 2023
The 30th Annual Meeting of the Huntington Study Group
HSG’s Annual Meeting provides interaction and collaboration with fellow researchers, clinicians, and industry leaders from around the world. The benefits of attending this meeting extend far beyond the immediate event, as the relationships forged and insights gained could lead to collaborative research opportunities, access to cutting-edge studies, and potential funding partnerships.
The 30th Annual Meeting of the Huntington Study Group
HSG’s Annual Meeting provides interaction and collaboration with fellow researchers, clinicians, and industry leaders from around the world. The benefits of attending this meeting extend far beyond the immediate event, as the relationships forged and insights gained could lead to collaborative research opportunities, access to cutting-edge studies, and potential funding partnerships.
View our poster and meet our team!
The Huntington Study Group (HSG) is a Huntington disease focused boutique CRO that conducts clinical trials and provides programs that impact research and care. With a mission to seek effective treatments that improve the quality of life for people affected by Huntington disease. The annual meeting includes popular research round-up panel discussions on current clinical trials and plenary, scientific, and research sessions.
Meet Corey Monteith, Senior Account Manager ‑ West Coast to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, and high-content imaging applications. Corey will also be presenting a poster on "Genotype and phenotype validation of an isogenic human iPSC-derived neuronal model of Huntington’s Disease". This scientific poster shows data validating both the genotype and phenotype of these cells, including gene and protein expression profiles, and electrophysiological analysis in comparison to an isogenic control.
In this poster, you will explore:
- How ioGlutamatergic Neurons HTT 50CAG/WT were generated using opti-ox precision cellular reprogramming and CRISPR-Cas9 genome engineering
- Data describing the genotype and phenotype of these cells, including RT-qPCR, ICC, Bulk-RNA seq and MEA, all in comparison to an isogenic control
- How ioGlutamatergic Neurons HTT 50CAG/WT form a powerful next-generation model to study Huntington’s disease in research and drug discovery
If you would like to arrange a meeting with Corey at the event please click below.
Arrange a meeting